Barreto Savio G, Brooke-Smith Mark, Dolan Paul, Wilson Thomas G, Padbury Robert T A, Chen John W C
Hepatopancreatobiliary Unit and South Australian Liver Transplant Unit, Flinders Medical Centre, Adelaide, South Australia, Australia.
ANZ J Surg. 2013 May;83(5):331-5. doi: 10.1111/j.1445-2197.2012.06196.x. Epub 2012 Sep 3.
Liver resection (LR) and liver transplantation (LT) are two modalities offering potential for cure in patients with hepatocellular carcinoma (HCC). The objective of this study was to evaluate the long-term survival of patients with HCC treated with LT and LR and to analyse variables influencing these outcomes.
Patients referred to the South Australian Liver Transplant Unit and Hepatopancreatobiliary Unit at Flinders Medical Centre from January 1992 to September 2009 with a diagnosis of HCC who underwent LT or LR were included in the study. Histopathological parameters analysed included size, number and grade of tumour, microscopic vascular invasion and presence or absence of cirrhosis in remnant liver.
Eighty-five patients with a median age of 58 years (range 26-85 years) underwent LT or LR. Median follow-up was 40 months in both groups. Overall, 5-year actuarial survival for all patients with HCC in both groups was 55%. LR patients were significantly older (P < 0.001) than LT patients. Their tumours were larger (P < 001) and more often solitary (P < 0.001) compared with the LT group. In multivariate analysis, age >60 (P < 0.02), histopathological evidence of vascular invasion (P < 0.02) and presence of cirrhosis (P < 0.02) were associated with a significantly reduced survival. Patients without vascular invasion and cirrhosis had an actuarial 5-year survival >70%.
Our study indicates that LT (within University of California, San Francisco criteria) and LR can lead to acceptable long-term survival outcomes in patients with HCC. Microscopic vascular invasion and cirrhosis were the most significant prognostic factors impacting on survival.
肝切除术(LR)和肝移植术(LT)是两种可为肝细胞癌(HCC)患者提供治愈可能的治疗方式。本研究的目的是评估接受LT和LR治疗的HCC患者的长期生存率,并分析影响这些结果的变量。
纳入1992年1月至2009年9月转诊至南澳大利亚肝移植中心和弗林德斯医疗中心肝胆胰外科、诊断为HCC并接受LT或LR的患者。分析的组织病理学参数包括肿瘤大小、数量和分级、微血管侵犯以及残余肝中有无肝硬化。
85例患者接受了LT或LR,中位年龄58岁(范围26 - 85岁)。两组的中位随访时间均为40个月。总体而言,两组所有HCC患者的5年精算生存率为55%。LR患者比LT患者年龄显著更大(P < 0.001)。与LT组相比,他们的肿瘤更大(P < 0.001)且更常为单发(P < 0.001)。多因素分析显示,年龄>60岁(P < 0.02)、微血管侵犯的组织病理学证据(P < 0.02)和肝硬化的存在(P < 0.02)与生存率显著降低相关。无微血管侵犯和肝硬化的患者5年精算生存率>70%。
我们的研究表明,LT(符合加利福尼亚大学旧金山分校标准)和LR可使HCC患者获得可接受的长期生存结果。微血管侵犯和肝硬化是影响生存的最重要预后因素。